Achieve Life Sciences, Inc. cash flow to debt ratio of -330.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Achieve Life Sciences, Inc.'s free cash flow has decreased 66.17% from $-29.77M last year to $-49.47M, signaling decreasing performance

Achieve Life Sciences, Inc.'s debt to equity ratio is 1.40, which means that the company's assets are unhealthy financed, signaling financial risk.

Achieve Life Sciences, Inc.'s debt has increased relative to shareholder equity from 0.48 last year to 1.40 today, signaling weakened financials

Achieve Life Sciences, Inc. has a net cash position, so leverage is healthy.

Achieve Life Sciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Achieve Life Sciences, Inc. has insufficient data to evaluate this check.

Achieve Life Sciences, Inc.'s short-term assets of $39.89M exceed its short-term liabilities of $9.08M

Achieve Life Sciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Achieve Life Sciences, Inc.'s return on equity of -193.49%, is lower than 15.00%, indicating bad performance

Achieve Life Sciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Achieve Life Sciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Achieve Life Sciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Achieve Life Sciences, Inc. has negative free cash flow, indicating cash burn

Achieve Life Sciences, Inc.'s yearly earnings has decreased 37.21% since last year from $-39.83M to $-54.65M, signaling decreasing performance

Achieve Life Sciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -194.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Achieve Life Sciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Achieve Life Sciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Achieve Life Sciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Achieve Life Sciences, Inc. has insufficient data to evaluate this check.

Achieve Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Achieve Life Sciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Achieve Life Sciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Achieve Life Sciences, Inc. has insufficient data to evaluate this check.

Achieve Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Achieve Life Sciences, Inc. has a price-to-book ratio of 33.35x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Achieve Life Sciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue